BUSINESS SEGMENT INFORMATION (Details) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Sep. 30, 2025	Sep. 30, 2024	Sep. 30, 2025	Sep. 30, 2024
Segment Reporting Information [Line Items]
Revenues	$ 3,563.5	$ 3,282.0	$ 10,435.9	$ 9,679.5
Operating income	396.6	254.1	1,117.1	870.2
Amortization of Intangible Assets	(69.5)	(63.7)	(207.4)	(186.0)
Net Restructuring Charges	(5.9)	(18.0)	(16.4)	(34.6)
Asset Impairment Charges	(0.7)	0.0	(0.7)	(2.5)
Goodwill and Intangible Asset Impairment			(0.7)	(2.5)
Interest expense	(56.0)	(50.4)	(169.1)	(144.9)
Investment income	3.5	3.1	11.7	7.3
Equity method loss, net	(5.2)	(0.5)	(7.2)	(0.7)
Other, net	(1.9)	4.3	(35.6)	43.8
Earnings before income taxes	337.0	210.6	916.9	775.7
Operating Segments
Segment Reporting Information [Line Items]
Operating income	582.6	508.3	1,723.1	1,575.0
Intersegment Eliminations
Segment Reporting Information [Line Items]
Revenues	5.2	9.2	17.3	34.2
Diagnostics
Segment Reporting Information [Line Items]
Labor and Related Expense	1,200.6	1,146.3	3,479.3	3,274.6
Supplies Expense	589.4	538.1	1,767.3	1,642.8
Other Cost and Expense, Operating	462.8	416.6	1,347.2	1,204.0
Diagnostics | Operating Segments
Segment Reporting Information [Line Items]
Revenues	2,769.6	2,553.5	8,148.0	7,558.1
Depreciation	66.4	65.1	193.5	189.9
Operating income	450.4	387.4	1,360.7	1,246.8
Biopharma Laboratory Services
Segment Reporting Information [Line Items]
Labor and Related Expense	313.8	293.1	905.8	869.2
Supplies Expense	119.5	109.5	361.4	319.7
Freight	101.8	93.7	295.0	271.8
Other Cost and Expense, Operating	102.8	89.0	294.0	273.7
Biopharma Laboratory Services | Operating Segments
Segment Reporting Information [Line Items]
Revenues	799.1	737.7	2,305.2	2,155.6
Depreciation	29.0	31.5	86.6	93.0
Operating income	132.2	120.9	362.4	328.2
Corporate Segment [Member]
Segment Reporting Information [Line Items]
Operating income	$ (109.9)	$ (172.5)	$ (381.5)	$ (481.7)